Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes
NCT ID: NCT07325305
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
60 participants
INTERVENTIONAL
2026-01-17
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Kids who are NOT losing muscle aren't part of the exercise trial - they're just monitored over time to see how they do.
The goal:
To see if an exercise program helps kids who are getting weaker from acute lymphoblastic leukemia treatment build back/maintain their strength, compared to kids who don't do the extra intervention. The study will also look at if this way of measuring muscle weakness works well for kids with cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Strength Training Exercises to Minimise Late Effects of Childhood Leukaemia or Lymphoma Among Adolescents
NCT06299722
Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors
NCT02501460
Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients
NCT05603585
Investigating the Anabolic Response to Resistance Exercise After Critical Illness (ARTIST-2)
NCT05261984
Nutrient Support to Body Composition and Healthy Ageing
NCT02529124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Children with signs of sarcopenia will be randomised to one of two groups:
1. Standard care only, or,
2. Physical activity and strengthening intervention plus activity tracking with a Fitbit (A wearable electronic activity tracker) This study will evaluate if the implementability of this intervention as well as the limited efficacy and investigate the framework for frailty used in this study.
It is known that children undergoing acute treatment for ALL experience signs of frailty from as early as 6 weeks post diagnosis. It is known that physical activity and exercise is safe and effective for children though it is most commonly conducted as a reactive therapy when children have already significantly deteriorated.
Very little is known regarding the pathophysiology that drives sarcopenia in children with cancer and there are no standardised diagnostic criteria, assessment tools or treatments. Often studies limit diagnosis to muscle ultrasound alone, omitting functional assessment. It has been recommended that a standardised criteria incorporating muscle mass (by ultrasound) and functional measurements (such as hand grip strength), should be established. This study aims to create a frailty framework including sarcopenia assessment ("muscle strength" and muscle mass "loss of muscle") as well as "slowness", "poor endurance", "low physical activity" as described in the outcome measurement section. This should contribute to a standardised criteria for sarcopenia as well as a criteria for identifying early signs of frailty with cut-offs.
The intervention aims to prevent frailty for participants with early signs of sarcopenia and currently there are no interventions that target frailty directly in children with cancer nor has frailty been investigated in the acute treatment phases of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observation cohort
These participants did not have early signs of sarcopenia at the post induction therapy assessment point, but will be followed up at all timepoints to better understand the natural progression of acute lymphoblastic leukaemia.
Usual care is a ward based physiotherapist service which is reactive and referral based only.
No interventions assigned to this group
Usual care control group
These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the control group. Usual care is a ward based physiotherapist service which is reactive and referral based only.
No interventions assigned to this group
Intervention group
These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching, as well as concurrently receiving 8 weeks of structured exercise sessions weekly (45-60 minutes per session x 3/week). These sessions are individualised based on the participant's functional performance outcomes from the assessment prior to randomisation, with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individual's development stage, age, interests and enjoyment.
Exercise
These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching (with activity tracking via Fitbit for continuous feedback) as well as concurrent 8 weeks of 3x45-60 minute structured exercise sessions weekly. These are individualised based on their functional performance outcomes from the assessment prior to randomisation with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individuals development stage, age, interests and enjoyment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
These participants demonstrated early signs of sarcopenia at the post induction phase of treatment assessment point and were randomised to the intervention group. The intervention group receives 9 weeks of goal setting and physical activity behaviour change coaching (with activity tracking via Fitbit for continuous feedback) as well as concurrent 8 weeks of 3x45-60 minute structured exercise sessions weekly. These are individualised based on their functional performance outcomes from the assessment prior to randomisation with a resistance strength training and progressive overload principles. The delivery of the specific exercises will be based on a pragmatic, participation based focus and will incorporate the individuals development stage, age, interests and enjoyment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* New diagnosis of acute lymphoblastic leukaemia \<7 days
* Is planned to receive management for their cancer treatment at the trial site for the duration of the trial period
* Has a legally acceptable representative capable of understanding the informed consent document in English and providing consent on the participant's behalf
* Have a family electronic device that can be linked with the tool to be used (Fitbit)
Exclusion Criteria
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Murdoch Childrens Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rachel Conyers, A/Prof Paediatric Oncologist
Role: STUDY_DIRECTOR
Murdoch Children's Research Institute, Royal Children's Hospital (Melbourne), University of Melbourne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Children's Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/ETH01569
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.